KRYSTAL BIOTECH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 159 USD | -2.35% |
|
-4.69% | +28.16% |
Presenter SpeechAlec Stranahan (Analysts)[Audio Gap] of the 2024 Bank of America Health Care C...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. It is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include VYJUVEK, KB407, KB408, KB707, KB105, KB104, KB104, and KB301. Its commercial product VYJUVEK is a non-invasive, topical, redo sable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds. VYJUVEK is designed to treat DEB at the molecular level by providing the patientâs skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism. KB407 is developed for the treatment of Cystic Fibrosis. KB408 is developed for the treatment of Alpha-1 Antitrypsin Deficiency. KB707 is developed for the treatment of solid tumors. KB105 is developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis.
Calendar
2024-11-03
- Q3 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
159
USD
Average target price
189
USD
Spread / Average Target
+18.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +28.16% | 4.54B | |
| +9.83% | 115B | |
| +10.80% | 105B | |
| -10.84% | 22.71B | |
| -0.47% | 21.83B | |
| -10.72% | 18.18B | |
| -41.92% | 16.52B | |
| -15.11% | 16.01B | |
| +6.62% | 14.14B | |
| +17.53% | 10.71B |
- Stock Market
- Equities
- KRYS Stock
- News Krystal Biotech, Inc.
- Transcript : Krystal Biotech, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 02
